Assessing anorectal function in patients with recurrent ulcerative colitis.
Humans
Colitis, Ulcerative
/ physiopathology
Male
Female
Adult
Recurrence
Middle Aged
Leukocyte L1 Antigen Complex
/ analysis
Feces
/ chemistry
Anal Canal
/ physiopathology
Rectum
/ physiopathology
Defecation
/ physiology
Prospective Studies
Fecal Incontinence
/ physiopathology
Anxiety
/ physiopathology
Anorectal function
Determinants
Relapse
Ulcerative colitis
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
accepted:
02
07
2024
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
15
7
2024
Statut:
epublish
Résumé
Ulcerative colitis (UC) is an inflammatory bowel disease with an unclear etiology that can lead to irreversible changes in distal colonic function in chronic patients. This study investigated anorectal function in recurrent UC patients and identified influencing factors. This prospective study enrolled 33 recurrent UC patients and 40 newly diagnosed patients from January 2019 to December 2022. Data collection included clinical records, scores, and anorectal function assessments. Regression analyses were used to identify factors impacting anorectal function. Recurrent UC patients had higher baseline CRP and fecal calprotectin levels, increased anxiety and depression, and more severe fecal incontinence. They also had lower BMIs, serum Hb and albumin (ALB) levels, and Inflammatory Bowel Disease Questionnaire scores than did initial-onset UC patients. Multivariate linear regression analysis revealed that long disease duration (coef. - 0.376, P < 0.001) and high fecal calprotectin level (coef. - 0.656, P < 0.001) independently influenced the initial sensation threshold in recurrent UC patients. Additionally, high fecal calprotectin (coef. - 0.073, P = 0.013) and high Zung Self-Rating Anxiety Scale score (coef. - 0.489, P = 0.001) were identified as two independent determinants of the defecation volume threshold. For the defecation urgency threshold, the independent factors included high disease duration (coef. - 0.358, P = 0.017) and high fecal calprotectin level (coef. - 0.499, P = 0.001). Similarly, the sole independent factor identified for the maximum capacity threshold was high fecal calprotectin (coef. - 0.691, P = 0.001). Recurrent UC patients had increased rectal sensitivity and compromised anorectal function, which significantly impacted quality of life. Proactively managing the disease, reducing UC relapses, and addressing anxiety are effective measures for improving anorectal function in these patients.
Identifiants
pubmed: 39009899
doi: 10.1007/s00384-024-04680-1
pii: 10.1007/s00384-024-04680-1
doi:
Substances chimiques
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110Informations de copyright
© 2024. The Author(s).
Références
Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T (2020) Ulcerative colitis. Nat Rev Dis Primers 6:74. https://doi.org/10.1038/s41572-020-0205-x
doi: 10.1038/s41572-020-0205-x
pubmed: 32913180
Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L (2022) Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 7:161–170. https://doi.org/10.1016/s2468-1253(21)00377-0
doi: 10.1016/s2468-1253(21)00377-0
pubmed: 34856198
Nidhi RM, Kaur V, Hallan SS, Sharma S, Mishra N (2016) Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: a brief review. Saudi Pharm J 24:458–472. https://doi.org/10.1016/j.jsps.2014.10.001
doi: 10.1016/j.jsps.2014.10.001
pubmed: 27330377
Ng SC, Kaplan GG, Tang W et al (2019) Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol 114:107–115. https://doi.org/10.1038/s41395-018-0233-2
doi: 10.1038/s41395-018-0233-2
pubmed: 30177785
Lam TJ, Van Bodegraven AA, Felt-Bersma RJ (2014) Anorectal complications and function in patients suffering from inflammatory bowel disease: a series of patients with long-term follow-up. Int J Colorectal Dis 29:923–929. https://doi.org/10.1007/s00384-014-1926-7
doi: 10.1007/s00384-014-1926-7
pubmed: 24965857
Hirten RP, Sands BE (2021) New therapeutics for ulcerative colitis. Annu Rev Med 72:199–213. https://doi.org/10.1146/annurev-med-052919-120048
doi: 10.1146/annurev-med-052919-120048
pubmed: 33502898
Sandborn WJ, Vermeire S, Peyrin-Biroulet L et al (2023) Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet 401:1159–1171. https://doi.org/10.1016/s0140-6736(23)00061-2
doi: 10.1016/s0140-6736(23)00061-2
pubmed: 36871574
Chen M, Ding Y, Tong Z (2020) Efficacy and safety of Sophora flavescens (Kushen) based traditional Chinese medicine in the treatment of ulcerative colitis: clinical evidence and potential mechanisms. Front Pharmacol 11:603476. https://doi.org/10.3389/fphar.2020.603476
doi: 10.3389/fphar.2020.603476
pubmed: 33362558
pmcid: 7758483
Celikbilek M, Dogan S, Ozbakır O, Zararsız G, Kücük H, Gürsoy S, Yurci A, Güven K, Yücesoy M (2013) Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal 27:72–76. https://doi.org/10.1002/jcla.21564
doi: 10.1002/jcla.21564
pubmed: 23292894
pmcid: 6807407
Norton C, Dibley LB, Bassett P (2013) Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohns Colitis 7:e302–e311. https://doi.org/10.1016/j.crohns.2012.11.004
doi: 10.1016/j.crohns.2012.11.004
pubmed: 23228710
Fukui R, Nozawa H, Sakamoto A, Sasaki K, Murono K, Emoto S, Ishihara S (2023) Temporal changes in functional outcomes of stapled and hand-sewn ileal pouch-anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Colorectal Dis 25:396–403. https://doi.org/10.1111/codi.16397
doi: 10.1111/codi.16397
pubmed: 36318592
Di Ruscio M, Variola A, Vernia F, Lunardi G, Castelli P, Bocus P, Geccherle A (2021) Role of ulcerative colitis endoscopic index of severity (UCEIS) versus mayo endoscopic subscore (MES) in predicting patients’ response to biological therapy and the need for colectomy. Digestion 102:534–545. https://doi.org/10.1159/000509512
doi: 10.1159/000509512
pubmed: 32739919
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ (2012) Ulcerative colitis. Lancet 380:1606–1619. https://doi.org/10.1016/s0140-6736(12)60150-0
doi: 10.1016/s0140-6736(12)60150-0
pubmed: 22914296
Eisenstein M (2018) Ulcerative colitis: towards remission. Nature 563:S33. https://doi.org/10.1038/d41586-018-07276-2
doi: 10.1038/d41586-018-07276-2
pubmed: 30405234
Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85–95. https://doi.org/10.1053/j.gastro.2013.05.048 . (quiz e14–e15)
doi: 10.1053/j.gastro.2013.05.048
pubmed: 23735746
Rao SS, Read NW, Davison PA, Bannister JJ, Holdsworth CD (1987) Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology 93:1270–1275. https://doi.org/10.1016/0016-5085(87)90255-1
doi: 10.1016/0016-5085(87)90255-1
pubmed: 3678745
Rao SS, Read NW, Brown C, Bruce C, Holdsworth CD (1987) Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 93:934–940. https://doi.org/10.1016/0016-5085(87)90554-3
doi: 10.1016/0016-5085(87)90554-3
pubmed: 3653643
Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K (2022) Real-world efficacy and safety monitoring for predicting continuation of tofacitinib therapy in patients with ulcerative colitis. Dig Dis Sci 67:3984–3992. https://doi.org/10.1007/s10620-021-07233-6
doi: 10.1007/s10620-021-07233-6
pubmed: 34460029
Farraye FA, Qazi T, Kotze PG, Moore GT, Mundayat R, Lawendy N, Sharma PP, Judd DT (2021) The impact of body mass index on efficacy and safety in the tofacitinib octave ulcerative colitis clinical programme. Aliment Pharmacol Ther 54:429–440. https://doi.org/10.1111/apt.16439
doi: 10.1111/apt.16439
pubmed: 34165201
pmcid: 8362064
Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV, Panes J, Danese S (2021) Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis. J Crohns Colitis 15:2022–2030. https://doi.org/10.1093/ecco-jcc/jjab099
doi: 10.1093/ecco-jcc/jjab099
pubmed: 34107013
pmcid: 8684481
Gu P, Kuenzig ME, Kaplan GG, Pimentel M, Rezaie A (2018) Fecal incontinence in inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 24:1280–1290. https://doi.org/10.1093/ibd/izx109
doi: 10.1093/ibd/izx109
pubmed: 29617820
Nigam GB, Limdi JK, Vasant DH (2018) Current perspectives on the diagnosis and management of functional anorectal disorders in patients with inflammatory bowel disease. Therap Adv Gastroenterol 11:1756284818816956. https://doi.org/10.1177/1756284818816956
doi: 10.1177/1756284818816956
pubmed: 30574193
pmcid: 6295686
Reenaers C, Bossuyt P, Hindryckx P, Vanpoucke H, Cremer A, Baert F (2018) Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J 6:1117–1125. https://doi.org/10.1177/2050640618784046
doi: 10.1177/2050640618784046
pubmed: 30288273
pmcid: 6169045
D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18:2218–2224. https://doi.org/10.1002/ibd.22917
doi: 10.1002/ibd.22917
pubmed: 22344983
Van Den Brink G, Stapersma L, Vlug LE, Rizopolous D, Bodelier AG, Van Wering H, Hurkmans P, Stuyt RJL, Hendriks DM, van der Burg JAT, Utens E, Escher JC (2018) Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease. Aliment Pharmacol Ther 48:358–369. https://doi.org/10.1111/apt.14832
doi: 10.1111/apt.14832
pubmed: 29897134
Gracie DJ, Guthrie EA, Hamlin PJ, Ford AC (2018) Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease. Gastroenterology 154:1635-1646.e3. https://doi.org/10.1053/j.gastro.2018.01.027
doi: 10.1053/j.gastro.2018.01.027
pubmed: 29366841